- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01490528
Durability and Tolerability of Infliximab in Pediatric Inflammatory Bowel Disease Patients: A 10 Year Single Center Experience
There is little data published on the long term durability of infliximab in pediatric patients. In particular a focus on durable remission, frequency of dose/frequency change and switch within class. Moreover 10 years of safety experience is rarely reported in children.
The overall objective is to evaluate the persistence of infliximab as well as dosing strategies in pediatric inflammatory bowel disease (IBD) patients and safety of infliximab Regarding persistence of infliximab the investigators will be focusing on the proportion of patients who continue to have a durable response or remission to infliximab.
The investigators will be assessing this by measuring the frequency of dose escalation, proportion of patients needing frequency change and proportion of patients switched to adalimumab or certolizumab.
Safety outcomes will focus on frequency of malignancies, infections and immunogenecity
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Marla Dubinsky, MD
- Email: dubinskym@csmc.edu
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All individuals who received at least 2 doses of infliximab before the age of 16 at the pediatric IBD Center at Cedars Sinai Medical Center for the treatment of Crohn's disease or ulcerative colitis Able to give consent
Exclusion Criteria:
- not exposed to infliximab
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Frequency of patients with a sustained durable remision and frequency of serious infections and malignancies in children exposed to infliximab
Time Frame: 10 years
|
10 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Frequency of concomitant immunomodulator use in children on infliximab
Time Frame: 10 years
|
10 years
|
Frequency of anti-drug antibodies in patients on and off comcomitant immunomodulators
Time Frame: 10 years
|
10 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marla Dubinsky, Cedar Sinai Medical Center
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- REMICADEIBD4008
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric Inflammatory Bowel Disease
-
McMaster UniversityCompletedPediatric Ulcerative Colitis | Pediatric Crohns Disease | Pediatric Inflammatory Bowel DiseasesCanada
-
Centre Hospitalier Universitaire, AmiensFunding from DGOS (PHRC IR 2013 and PRME)CompletedPediatric Inflammatory Bowel DiseaseFrance
-
Klinikum Westbrandenburg GmbHUnknown
-
McMaster Children's HospitalSt. Justine's HospitalCompletedInflammatory Bowel Diseases | Crohn Disease | Colitis | Pediatric Crohns DiseaseCanada
-
Laura MacknerChildren's Hospital Medical Center, CincinnatiRecruitingInflammatory Bowel Diseases | Pediatric Ulcerative Colitis | Pediatric Crohns DiseaseUnited States
-
Cardiff and Vale University Health BoardRecruitingInflammatory Bowel Diseases | Crohn Disease | Ulcerative Colitis | Pediatric Ulcerative Colitis | Pediatric Crohns DiseaseUnited Kingdom
-
Hôpital Necker-Enfants MaladesInstitut National de la Santé Et de la Recherche Médicale, France; NestléUnknownCrohn's Disease | PediatricFrance
-
Hospices Civils de LyonNot yet recruitingCrohn Disease | Pediatric Crohns DiseaseFrance
-
Children's Hospital Los AngelesCompleted
-
University of North Carolina, Chapel HillUniversity of Amsterdam; Crohn's and Colitis FoundationRecruitingCrohn Disease | Pediatric Crohns DiseaseNetherlands, United States, Canada, Israel